マサムネ　ケン   Masamune Ken   正宗　賢    所属   医学研究科 医学研究科 (医学部医学科をご参照ください)    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	The high incidence and risk factors of levetiracetam and lacosamide-related skin rashes in glioma patients
掲載誌名	正式名：Clinical neurology and neurosurgery 略　 称：Clin Neurol Neurosurg ISSNコード：03038467/18726968
掲載区分	国外
巻・号・頁	220,pp.107366
著者・共著者	ONODERA Mikoto†, SAITO Taiichi, FUKUI Atsushi, NITTA Masayuki, TSUZUKI Shunsuke, KORIYAMA Shunichi, MASAMUNE Ken, KAWAMATA Takakazu, MURAGAKI Yoshihiro
発行年月	2022/06/10
概要	Antiseizure drug (ASD)-induced skin rash remains the main side effect of seizure management in patients with glioma. New generations of ASDs, such as levetiracetam (LEV) and lacosamide (LCM) are associated with less frequent skin rashes than conventional ASDs. However, there are few reports regarding the incidence of skin rashes by LEV and LCM in patients with glioma. Therefore, the aim of this study was to investigate the incidence and risk factors of LEV- and LCM-associated skin rashes in patients with glioma. We compared the incidence of ASD-associated skin rash between 353 patients with glioma and 125 patients with meningioma, who received LEV or LCM and underwent surgery between 2017 and 2019 at our institution. Furthermore, to evaluate the association between potential risk factors and ASD-associated skin rashes, univariate and multivariate analyses were performed. The incidence of ASD-associated skin rash in patients with glioma was higher (11%) than in those with meningiomas (1.6%). The multivariate regression analysis showed that adjuvant treatment with radiotherapy (p = 0.023) and a history of drug allergy (p = 0.023) were significant risk factors for ASD-associated skin rash. The rate of ASD-related skin rashes in patients with glioma was also higher than the previously reported rates of 1-3% in patients with epilepsy. Our results indicate that adjuvant treatment with radiotherapy and a history of drug allergy correlated with a high incidence of ASD-related skin rashes in patients with patients who receive LEV and LCM. Patients with these two factors should be carefully checked for skin rashes.
DOI	10.1016/j.clineuro.2022.107366